T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

T2 Biosystems (TTOO) stock is on the rise Tuesday following positive news concerning testing for new strains of the novel coronavirus. The post TTOO Stock: 10 Things to Know About T2 Biosystems Today appeared first on InvestorPlace.

TTOO Stock: 10 Things to Know About T2 Biosystems Today

As the COVID-19 virus mutates into different variants, one small-cap diagnostics company says their test can detect the mutated strains: T2 Biosystems. T2 Biosystems soared as much as 49% in Tuesday pre-market trades after it said its T2SARS-CoV-2 Panel proved effective in identifying variants of COVID-19 that are spreading quickly in the UK, South Africa, and the US.

T2 Biosystems jumps 49% after saying its diagnostic test can detect COVID-19 variants (TTOO)

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

T2 Biosystems (TTOO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

T2 Biosystems (TTOO) Jumps: Stock Rises 8.7%

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile failures like hedge funds' 2018 losses in Facebook and Apple. Let's take a closer look at what the funds we track think about T2 Biosystems Inc (NASDAQ:TTOO) in this article.

Where Do Hedge Funds Stand On T2 Biosystems Inc (TTOO)?

A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.

T2 Biosystems: Pandemic Boost Increases Chance Of Long-Term Success

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.

T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript

T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

T2 Biosystems (TTOO) Reports Q3 Loss, Tops Revenue Estimates

Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08), which were in line with the estimate of ($0.08).

T2 Biosystems: Q3 Earnings Insights

Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales

T2 Biosystems Announces Third Quarter 2020 Financial Results

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2020 after market close on Wednesday, November 4, 2020. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020

Is (TTOO) Outperforming Other Medical Stocks This Year?

Is T2 Biosystems (TTOO) Outperforming Other Medical Stocks This Year?

Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens

T2 Biosystems Announces BARDA Exercise of Contract Option 1 Valued at $10.5 Million

Is  (TTOO) Outperforming Other Medical Stocks This Year?

Is T2 Biosystems (TTOO) Stock Outpacing Its Medical Peers This Year?

Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus

T2 Biosystems to Participate in Sepsis Alliance Summit

Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients

T2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year

The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument

T2 Biosystems Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test

Cerus

Kamada

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

3 Plasma Stocks to Win Big on FDA's Convalescent EUA

ADMA Biologics

Grifols, S.A.

Liminal BioSciences

Sonnet BioTherapeutics

ThermoGenesis Holdings, Inc

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

Do Options Traders Know Something About T2 Biosystems (TTOO) Stock We Don't?

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript

Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.

Recap: T2 Biosystems Q2 Earnings

LEXINGTON, Mass., Aug.  11, 2020  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the second quarter ended June 30, 2020.

News for T2 Biosystems Stock (TTOO)